COMBATTING URGENT VIRAL DISEASE THREATS

DR DAVID FOSTER, MANAGING DIRECTOR

July 2025

(ASX: ILA)

DISCLAIMER

This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (**Company** or **Island Pharmaceuticals**).

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Financial data All dollar values are in Australian dollars ($ or A$) unless otherwise stated. Any financial data in this presentation is unaudited. Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics company targeting infectious diseases

Galidesivir acquisition executed - expedited approval route defined

Major market potential

Positive results in aggressive models

Phase 2a/b PROTECT clinical trial in dengue completed

2x potential PRVs valued at ~A$225m each

Dengue infects up to 400m per year*

CORPORATE OVERVIEW

Snapshot

Shares on issue[1]:	236,093,034
Price per share[1]:	$0.145
Market capitalisation[1]:	$34.24m
Cash at bank (31 March 2024)[2]:	$4.82m
May 2025 capital raise:	$3.6m
DoD grant funding to directly support the Phase 2a/b PROTECT clinical study	US$625k

Substantial shareholders	
Dr William James Garner[3]	14.21%
Jason Carroll[4]	13.26%
MWP Partners Limited[5]	8.25%
Dr Daniel Tillett[6]	6.72%

1. As at 7 July 2025
2. Does not take into consideration cash used since reporting date
3 Per holding per Substantial interest notices lodged with ASX on 02 June 2025

Price & volume (12 month)



Board of Directors

Jason Carroll, Non-Executive Chairman
Dr David Foster, CEO and Managing Director
Chris Ntoumenopoulos , Non-Executive Director

4. Per holding per Substantial interest notices lodged with ASX on 29 May 2025
5 Per holding per Substantial interest notices lodged with ASX on 03 June 2025
6 Per holding per Substantial interest notices lodged with ASX on 19 March 2025

BENEFITS OF DRUG REPURPOSING



***De novo* Drug Discovery and Development**
- Low Success Rate
- Huge Cost and Time-consuming Development

Drug Repurposing
- Known Drug Safety
- Reduced Pharmacokinetic Uncertainty

Drug Repurposing

ILA is well advanced in its clinical development pipeline

GALIDESIVIR ACQUISITION TRANSACTION

- Asset acquisition of galidesivir and related compounds
- Clinical program and robust pre-clinical data package
- International IP portfolio
- Favourable terms:
  - Upfront $550,000 USD including $50,000 option fee
  - US$500,000 upon completion of Phase 2 clinical trial
  - US$1M upon approval of New Drug Application in US or equivalent or US$1.5M upon Animal Rule approval in which no Phase 2 is required
  - Tiered royalties of 5-10% of Net Sales
  - 25% of proceeds from sale of any Priority Review Voucher awarded due to FDA approval of the acquired program(s)

GALIDESIVIR PROGRAM

Program was developed in collaboration with NIAID (>US$70m in funding to date) to prepare for and respond to high priority virus threats and emerging viral infections

- Asset purchase agreement executed with NASDAQ-listed, BioCryst Pharmacueticals Inc. (Nasdaq: BCRX) with favorable transaction terms
- Program commenced to target high-priority threats (Marburg and Ebola) and was expanded to include development for MERS, Zika and Yellow Fever as potential for emerging infectious disease outbreaks
- Shown to be **active against more than 20 RNA viruses in nine different families** (filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, orthomyxoviruses, picornaviruses and flaviviruses)
- **Demonstrated survival benefits in animal studies** against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses
- **Safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials** by both intravenous and intramuscular routes of administration in healthy subjects
- Potential to **expedite approval with work underway to advance clinical trials**

GALIDESIVIR PROGRAM SUMMARY

GALIDESIVIR UNLOCKS ANOTHER MAJOR MARKET

- Demonstrated activity against 20+ viruses – many with no available treatment
- Activity against potential bioterror threats
- Potential markets:
  - Government stockpile programs
  - Numerous antiviral programs
  - Ripe potential for partnering

BROAD SPECTRUM ACTIVITY DEMONSTRATED

Data highlights activity in vitro against multiple RNA viruses from diverse families

Virus Family	Virus	Strain/Variant
Filoviridae	Marburg	Musoke
	Marburg	Ci67
	Marburg	Angola
	Ebola	Kikwit
	Sudan	Boniface
Togaviridae	VEE	SH3
	EEE	FL93-939
	WEE	California
	Chikungunya	AF 15561
Bunyaviridae	Rift Valley Fever	ZH501
	LaCrosse encep	Wisc 1960
	Maporal virus	HV97021050
Arenaviridae	Lassa	Josiah
	Junin	Romero

Virus Family	Virus	Strain/Variant
Paramyxo	Nipah virus	Malaysia
	HRS	A2
	Measles	Chicago
Corona	SARS-CoV	Urbani
	MERS-CoV	Jordan
Orthomyxo	Influenza	pH1N1
Picornaviridae	Rhinovirus-2	HGP
Flaviviridae	West Nile	New York
	Yellow fever	17D
	Jap. Enceph.	SA14
	Powassan Virus	LB
	Dengue 2	New Guinea C
	Zika	PRVABC59

MULTIPLE PHASE 1 HUMAN SAFETY CLINICAL STUDIES

Phase1 HV – SAD / MAD IM
Study 101

SAD
Highest Dose: 10 mg/kg
MAD
Highest Dose: 10 mg/kg 7 days

✓ Completed

Phase1 HV – SAD IV
Study 106

Cohort 1: 5 mg/kg
Cohort 2: 10 mg/kg
Cohort 3: 15 mg/kg
Cohort 4: 20 mg/kg

✓ Completed

Phase 1b YF & COVID-19 – MAD
Study 108
(Part 1 Dosing Ranging)

Cohort 1: 10 mg/kg then 2 mg/kg q12h×13
Cohort 2: 10 mg/kg then 5 mg/kg q12h×13
Cohort 3: 20 mg/kg then 5 mg/kg q12h×13

Enrolled 24 subjects but trial terminated early

Opened but terminated prior to completion

Key Terms	
SAD	Single Ascending Dose
MAD	Multiple Ascending Dose

DEMONSTRATED IN VIVO ANTIVIRAL EFFECTS

Impact achieved with delayed dosing across a broad range of viruses

Animal Species	Virus	Dose Regimen	Key Results
Hamsters	Yellow Fever	100 mg/kg BID 7 days	100% survival initial dose 3dpi, 80% survival initial dose 4dpi[a]; 12.5% survival control
Rhesus NHP	Zika	100 mg/kg BID, 25 mg/kg BID 9 days	Viral load suppression initial dose 3dpi[b]; 0% survival control.
Cynomolgus NHP	Marburg	15 mg/kg BID 14 days	100% survival initial dose 2dpi[c]; 0% survival control.
Rhesus NHP	Ebola	100 mg/kg BID loading, 25 mg/kg BID 10 days	100% survival initial dose 2dpi, 67% survival initial dose 3 dpi[d]; 0% survival control.

Key terms	
BID	Twice Daily
2dpi	2 days post infection
3dpi	3 days post infection

Hamster YFV



Rhesus ZKV



Rhesus EVD



EFFICACY IN NHPS INFECTED WITH MARV



Figure a: **survival**
Animals (n=6/group) were challenged with MARV by SC injection, and Galidesivir (15mg/kg BID) or vehicle was administered IM beginning 1 hr (RED) 24 hr (BLUE) or 48 hr (GREEN) after challenge. Vehicle control (WHITE).

*P<0.05 for comparison of treatment versus vehicle by log-rank (Mantel–Cox) test

Key Terms	
NHPS	Non-human primates
MARV	Marburg virus
BID	Twice daily
Vehicle	Placebo injection containing no active treatment
PI	Post infection
SC	Subcutaneous
IM	Intramuscular

SUPPRESSION OF MARBURG VIRUS PROLIFERATION IN INFECTED NHPS



Figure b: viral load
Serum viral RNA load was determined in animals (n=6 per group) treated IM beginning 1 hr (RED) 24 hr (BLUE) or 48 hr (GREEN) after challenge. Vehicle control (WHITE).

*P<0.05 for comparison of treatment versus vehicle by two-tailed analyses using the Holm–Sidak method

POTENTIAL REGULATORY PATH



Potential that one additional successful animal study in Marburg may be required for NDA submission – ILA aims to complete trial within the next 12 months from closing

Likely Priority Review resulting in ~6-month FDA Review, alongside PRV potential

IMMEDIATE NEXT STEPS

Island focused on a near term program to unlock value

- Completion of all asset transfer from BioCryst to Island
- Finalise enquiries with US FDA
- Consult US FDA regarding potential for Animal Rule inclusion
- Ongoing review of data package
- Preparations for NHP studies

Island Pharmaceuticals (ASX: ILA)


islandpharmaceuticals.com


@IslandPharma


Island Pharmaceuticals

APPENDIX 1: SOURCES

Slide 12:

[a] Julander J. G et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother 2014;58(11):6607—14

[b] Whitney, J. B. et al. Galidesivir, a direct-acting antiviral, abrogates viremia in rhesus macaques challenged with Zika virus. Oral Presentation ID Week 2017

[c] Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405, doi:10.1038/nature13027 (2014)

[d] Warren, T. K. et al. Efficacy of Galidesivir Against Ebola Virus Disease in Rhesus Monkeys. Poster Presentation ID Week 2017

Slide 13:

Warren, T. K., J. Wells, R. G. Panchal, K. S. Stuthman, N. L. Garza, S. A. Van Tongeren, L. Dong, C. J. Retterer, B. T. Eaton, G. Pegorago, S. Honnold, S. Bantia, P. Kotian, B. R. Taubenheim, L. S. Welch, D. M. Minning, Y. S. Babu, W. P. Sheridan and S. Bavari (2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430." Nature: Advance Online Publication (AOP) March 2, 2014,

Slide 14:

Warren, T. K., J. Wells, R. G. Panchal, K. S. Stuthman, N. L. Garza, S. A. Van Tongeren, L. Dong, C. J. Retterer, B. T. Eaton, G. Pegorago, S. Honnold, S. Bantia, P. Kotian, B. R. Taubenheim, L. S. Welch, D. M. Minning, Y. S. Babu, W. P. Sheridan and S. Bavari (2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430." Nature: Advance Online Publication (AOP) March 2, 2014, http://dx.doi.org/10.1038/nature13027